Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avantor, Inc.AVTR · Entity 3546 | Director | May 08, 2025 | May 12, 2025 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Director | June 08, 2023 | June 12, 2023 |
| Moderna, Inc.MRNA · Entity 2025 | Chief Operating Officer | October 05, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avantor, Inc.
Report date May 08, 2025 · Filed May 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,480 |
Reported balance
After 2025-05-08 transaction · row 1
1 source rowRow 1 · 2025-05-08 · Grant · Acquired 17,100 · Balance 65,480 F1: Reflects a grant of restricted stock units that vests on May 08, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units that vests on May 08, 2026.
Evelo Biosciences, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.11 · Expires 2033-06-08 | Direct | 20,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests on the earlier of June 8, 2024 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 8, 2024 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.
Moderna, Inc.
Report date October 05, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 125,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 24, 2021 Filed Nov 26, 2021 19:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $273.01 | $1,365,050.00 |
DisclosureSEC source: 0000899243-21-046139 · doc4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 24, 2021 Filed Nov 26, 2021 19:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0000899243-21-046139 · doc4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 23:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0000899243-21-045849 · doc4.xml · derivative · entry 8 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 23:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0000899243-21-045849 · doc4.xml · derivative · entry 7 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,629 Underlying: Common Stock · 10,000 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 23:16 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $268.18 | $4,022,700.00 |
DisclosureSEC source: 0000899243-21-045849 · doc4.xml · nonDerivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 23:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0000899243-21-045849 · doc4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 23:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $14.22 | $142,200.00 |
DisclosureSEC source: 0000899243-21-045849 · doc4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 23:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0000899243-21-045849 · doc4.xml · derivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 23:16 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $265.71 | $1,328,550.00 |
DisclosureSEC source: 0000899243-21-045849 · doc4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 23:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0000899243-21-045849 · doc4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-029687 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $234.57 | $1,172,850.00 |
DisclosureSEC source: 0001127602-21-029687 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-029687 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 21:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-029325 · form4.xml · derivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 21:23 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $231.01 | $1,155,050.00 |
DisclosureSEC source: 0001127602-21-029325 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 21:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-029325 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-029325 · form4.xml · derivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:23 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $225.86 | $1,129,300.00 |
DisclosureSEC source: 0001127602-21-029325 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-029325 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-028963 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:16 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $230.00 | $1,150,000.00 |
DisclosureSEC source: 0001127602-21-028963 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-028963 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:36 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-028715 · form4.xml · derivative · entry 8 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:36 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-21-028715 · form4.xml · derivative · entry 7 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,629 Underlying: Common Stock · 10,000 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:36 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $233.13 | $3,496,950.00 |
DisclosureSEC source: 0001127602-21-028715 · form4.xml · nonDerivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:36 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-028715 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:36 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $14.22 | $142,200.00 |
DisclosureSEC source: 0001127602-21-028715 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:36 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-028715 · form4.xml · derivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:36 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $240.00 | $1,200,000.00 |
DisclosureSEC source: 0001127602-21-028715 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:36 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-028715 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 21:09 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-028499 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 21:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $350.00 | $1,750,000.00 |
DisclosureSEC source: 0001127602-21-028499 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 21:09 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-028499 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-028079 · form4.xml · derivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $335.00 | $1,675,000.00 |
DisclosureSEC source: 0001127602-21-028079 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-028079 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-028079 · form4.xml · derivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $344.49 | $1,722,450.00 |
DisclosureSEC source: 0001127602-21-028079 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-028079 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-027820 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $344.25 | $1,721,250.00 |
DisclosureSEC source: 0001127602-21-027820 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-027820 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,822 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-027654 · form4.xml · derivative · entry 10 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 9,822 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-027654 · form4.xml · derivative · entry 9 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,822 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 178 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-21-027654 · form4.xml · derivative · entry 8 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,629 Underlying: Common Stock · 178 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $327.36 | $4,910,400.00 |
DisclosureSEC source: 0001127602-21-027654 · form4.xml · nonDerivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 9,822 | $12.21 | $119,926.62 |
DisclosureSEC source: 0001127602-21-027654 · form4.xml · nonDerivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-027654 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 178 | $14.22 | $2,531.16 |
DisclosureSEC source: 0001127602-21-027654 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. Read SEC document |
| October 22, 2021 Filed Oct 26, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-027654 · form4.xml · derivative · entry 7 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,822 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.